AU2022254741A1 - Treatment of cancer with kdm4 inhibitors - Google Patents

Treatment of cancer with kdm4 inhibitors Download PDF

Info

Publication number
AU2022254741A1
AU2022254741A1 AU2022254741A AU2022254741A AU2022254741A1 AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1 AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1
Authority
AU
Australia
Prior art keywords
cancer
fold
diagnosed
patient
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022254741A
Other languages
English (en)
Inventor
Young K. Chen
Michael Clarke
Frank Perabo
Jeffrey A. Stafford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tachyon Therapeutics Inc
Celgene Corp
Original Assignee
Tachyon Therapeutics Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tachyon Therapeutics Inc, Celgene Corp filed Critical Tachyon Therapeutics Inc
Publication of AU2022254741A1 publication Critical patent/AU2022254741A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022254741A 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors Pending AU2022254741A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173219P 2021-04-09 2021-04-09
US63/173,219 2021-04-09
US202163252542P 2021-10-05 2021-10-05
US63/252,542 2021-10-05
US202263297960P 2022-01-10 2022-01-10
US63/297,960 2022-01-10
PCT/US2022/024087 WO2022217100A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Publications (1)

Publication Number Publication Date
AU2022254741A1 true AU2022254741A1 (en) 2023-11-16

Family

ID=83545127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022254741A Pending AU2022254741A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Country Status (6)

Country Link
US (1) US20250025451A1 (https=)
EP (1) EP4319748A4 (https=)
JP (1) JP2024518712A (https=)
AU (1) AU2022254741A1 (https=)
CA (1) CA3214399A1 (https=)
WO (1) WO2022217100A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600301B1 (en) 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
KR20250067936A (ko) * 2022-09-21 2025-05-15 셀진 코포레이션 3-({[(4r)-7-{메틸[4-(프로판-2-일)페닐]아미노}-3,4-디하이드로-2h-1-벤조피란-4-일]메틸}아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307643D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
UY35395A (es) * 2013-03-12 2014-10-31 Abbvie Inc Inhibidores de bromodominios tetracíclicos
SI3160952T1 (sl) * 2014-06-25 2021-07-30 Celgene Quanticel Research, Inc. Zaviralci histon demetilaz
EP3600301B1 (en) * 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
WO2019083594A1 (en) * 2017-08-21 2019-05-02 The General Hospital Corporation COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2023023112A1 (en) * 2021-08-18 2023-02-23 Celgene Corporation Process for preparing histone demethylase inhibitors

Also Published As

Publication number Publication date
EP4319748A1 (en) 2024-02-14
WO2022217100A1 (en) 2022-10-13
EP4319748A4 (en) 2025-02-26
JP2024518712A (ja) 2024-05-02
US20250025451A1 (en) 2025-01-23
CA3214399A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
Manni et al. JMJD family proteins in cancer and inflammation
JP7323592B2 (ja) 癌を治療するための併用療法
US20220062240A1 (en) Methods of treating cancer using a clk inhibitor
Campagna et al. Nicotinamide N‐methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines
JP7462789B2 (ja) Idh1阻害剤耐性対象の治療方法
US20250025451A1 (en) Treatment of cancer with kdm4 inhibitors
AU2020417223A1 (en) Treatment of cancer with CDK12/13 inhibitors
WO2012178038A1 (en) Methods of treating cancer
Soucie et al. Molecular basis of mast cell disease
JP7163495B2 (ja) B細胞リンパ腫の治療のための医薬組成物
CN116209452A (zh) 用于治疗aml的疗法和rara激动剂、低甲基化剂和bcl-2抑制剂的用途
US8598188B2 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US20210079384A1 (en) Non-invasive detection of response to a targeted therapy
WO2015134603A2 (en) Methods for treating cancer
JPWO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
CN114574580A (zh) 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
US20210260057A1 (en) Compositions and methods targeting glutamine and its metabolism for diagnosing and treating cancer and therapy-associated side effects
JP2022513375A (ja) NAMPTi感受性のバイオマーカーとしてのPPM1D変異の同定法
Liu et al. RHCG inhibition promotes the sensitivity of PIK3CA-mutant non-small lung cancer to PI3K inhibitor [J]
CN116904588B (zh) Linc01633在胃癌诊断和治疗中的应用
JPWO2011078312A1 (ja) 肝細胞癌患者に対する化学療法の治療効果予測方法
US20220184029A1 (en) Compositions and methods for treating neuroblastoma
CA3036568C (en) Methods for treating ovarian cancer
Zhou et al. PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development
Zhang et al. RETRACTED: L1-ATP8B1 Exacerbates High-Level Reduction-Oxidation Homeostasis to Promote Carcinogenesis via Affecting PHB1 Sumoylation in LUSC